agenebio logo
  • About Us
    • Management
    • Board of Directors
    • Job Opportunities
  • Pipeline
    • AGB101 for MCI due to AD
    • About MCI due to Alzheimer’s Disease
    • Novel GABA(A) α5 Discovery Program
  • The Science
  • Newsroom
  • Publications
  • Investor Relations
  • Patient Resources
    • MCI due to Alzheimer’s Disease
    • Autism
    • Schizophrenia

9th International Conference on Clinical Trials for Alzheimer’s Disease

Vice President of Clinical Development Richard Mohs, PhD, presented at this international conference on Alzheimer’s drug discovery sponsored by the Alzheimer’s Drug Discovery Foundation.

Recent Posts

  • Recent Report That Levetiracetam Could Stop the Plaque Formation of Alzheimer’s Disease in Its Earliest Stages Is Further Confirmation of The Positive Effects of AgeneBio’s Novel Therapeutic Approach to Treating Alzheimer’s Disease
  • The Alzheimer’s Association International Conference (AAIC) Toronto July 27-31 2025
  • Medical News Today: Could a once-daily pill for seizures also treat Alzheimer’s disease?
  • AgeneBio’s Phase 2B Trial Shows AGB101 Slows Progression of Brain Atrophy in Patients with Mild Cognitive Impairment Due to Alzheimer’s Disease Who Are Non-Carriers of the APoE-4 Allele
  • AgeneBio Founder Michela Gallagher Presents Hope4MCI Results at 12th Alzheimer’s & Parkinson’s Drug Development Summit

Recent Comments

  • millpettata1985 on Home
  • Digital Profit on Home

Archives

  • February 2026
  • August 2025
  • October 2024
  • April 2024
  • March 2024
  • November 2022
  • December 2021
  • August 2021
  • July 2021
  • April 2021
  • February 2021
  • January 2021
  • July 2020
  • June 2020
  • December 2019
  • November 2019
  • September 2019
  • May 2019
  • January 2019
  • October 2018
  • April 2018
  • March 2018
  • February 2018
  • September 2017
  • July 2017
  • June 2017
  • December 2016
  • September 2016
  • February 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • July 2015
  • April 2015
  • March 2015
  • January 2015
  • November 2014
  • July 2014
  • March 2014
  • October 2012
  • August 2012
  • May 2012
  • July 2011

Categories

  • Events
  • In the News
  • Recent News

Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org
agenebio therapeutic solutions for neurodegeneration

agenebio logo

AgeneBio, Inc.
1340 Smith Avenue, Suite 200
Baltimore, MD 21209

P: 410.779.1260

AgeneBio-Inc

@AgeneBio

 

  • Privacy Policy
  • Terms of Use

©2026 AgeneBio, Inc. All rights reserved.

Quick Links

  • About Us
    • Management
    • Board of Directors
    • Job Opportunities
  • Pipeline
    • AGB101 for MCI due to AD
    • About MCI due to Alzheimer’s Disease
    • Novel GABA(A) α5 Discovery Program
  • The Science
  • Newsroom
  • Publications
  • Investor Relations
  • Patient Resources
    • MCI due to Alzheimer’s Disease
    • Autism
    • Schizophrenia
  • Privacy Policy
  • Terms of Use

©2026 AgeneBio, Inc. All rights reserved.

Top